Douglas K Marks

Medical oncologist. Breast cancer specialist. New Yorker. Closet DIY enthusiast. Tweets my views alone.

[IDEOlogy Health @IDEOlogyHealth]

Join us live on X tonight at 9:30 pm Central for our IDEO Xchange discussing the latest developments in #breastcancer with Drs. @Dr_RShatsky @hoperugo @AbiSivaMD @mabelonc @DrWGradishar @MeganKruseMD @gandhi_shipra @dougmarksmd @Neil_Iyengar @kristinrojasmd @NinaOncMD @PriscilaBCMD

[Doctor Radio @NYUDocs]

A #breastcancer diagnosis doesn’t have to upend your whole life!
A special thanks to @Perlmutter_CC’s Dr. Doug Marks (L) & @Kathie_JosephMD for joining @nyulangone’s @MarkPochapin (R) on #ChiefsRounds!
Missed our conversation?
https://t.co/4JyGqF4bZ1 to listen on your schedule!

[Douglas K Marks @dougmarksmd]

Adding AKT Inhibitor Doubles PFS in Advanced, HR-Positive Breast Cancer https://t.co/U8NhSw9ybF

[Douglas K Marks @dougmarksmd]

TALENT Trial - hinting at the beginning of the end of cytotoxic chemotherapy. With targeted chemotherapy by ADC, replacing conventional cytotoxics. #sabcs2022

[Perlmutter Cancer Center at NYU Langone Health @Perlmutter_CC]

Join our medical oncologist Dr. Douglas Marks on @NYUDocs, tomorrow, August 2 at 9 am ET as he discusses the updated @ASCO guidelines on optimal adjuvant chemotherapy and targeted therapy for breast cancer. @SIRIUSXM (Channel 110).

[Douglas K Marks @dougmarksmd]

Trastuzumab Deruxtecan Is New Standard of Care for HER2-Low MBC https://t.co/2MchL4ocb4 via @onclive. While most oncs who prev rx TDxd are not surprised, still so impressed! Best said, these are modular drugs. Homerun here, and more to come #ADC #ASCO22

[Douglas K Marks @dougmarksmd]

Tumor Immune Microenvironment and Response to Neoadjuvant Chemotherapy... https://t.co/vKjo6z1pYv Columbia colleagues, continue the multiplex in her2 . Similar findings across Non-luminal subtypes

[Douglas K Marks @dougmarksmd]

Glad no longer in this phase of the pandemic! Grateful to my colleagues for working with me on this! This one is dedicated to our patients who bravely navigated their diagnoses amid the uncertainty of the early pandemic @Perlmutter_CC @perlmutterproud

https://t.co/1w9fhYIsd6

[Perlmutter Cancer Center at NYU Langone Health @Perlmutter_CC]

Our cancer experts just published in @OncJournal on the outcomes of breast cancer patients being treated during the #COVID19 pandemic.

Read more about the findings from this study: https://t.co/0fJOSMdflJ

[Douglas K Marks @dougmarksmd]

FDA Approves Adjuvant Olaparib for BRCA+, High-Risk Early Breast Cancer https://t.co/51ImyrOTda via @onclive. Targeted therapies for adjuvant management of high risk TNBC — IO and now germline pts with PARP. Great to see the needle moving.

[Perlmutter Cancer Center at NYU Langone Health @Perlmutter_CC]

Medical oncologist @AbreoNina leads a trial for HER2-positive #breastcancer to determine the safety and tolerability of pre-operative therapy with 12 weeks of taxane, trastuzumab (or FDA approved biosimilar) and pertuzumab. 

Learn more: https://t.co/raAzKmnAZA

[Douglas K Marks @dougmarksmd]

Despite initial fairly negative Fda review — now approved. IO metrics will differ from conventional therapy, pCR inc/ EFS shines. Will be a theme

[Reuters Health @Reuters_Health]

Merck & Co Inc (MRK.N) said on Tuesday that the U.S. Food and Drug Administration approved its immunotherapy Keytruda as a treatment for an early form of a tough-to-treat breast cancer in combination with chemotherapy. https://t.co/1tfYjwZMJP

[Douglas K Marks @dougmarksmd]

https://t.co/F6P6wFTLxw

[Douglas K Marks @dougmarksmd]

Study Examines Relationship Between Risk of COVID-19 Infection and Breast Cancer Treatment - The ASCO Post https://t.co/GLYJGNQADO

[Douglas K Marks @dougmarksmd]

Chemotherapy does not increase COVID-19 risk vs. noncytotoxic therapies for breast cancer https://t.co/lMpbNggjPo

[BreastCancerResearch @BCRJournal]

Quantitative stain-free imaging and digital profiling of collagen structure reveal diverse survival of triple negative breast cancer patients

Read for free! https://t.co/7qRlM9R6YJ

#Quantitativeimaging #Stroma #BreastCancer

[Douglas K Marks @dougmarksmd]

https://t.co/3Cj6Y644W2 collateral damage - well said. Need to adjust to new normal quickly as to limited the lasting impact this will have

[ASCO @ASCO]

📢 #ASCO20 Virtual Scientific Program 👉 Friday, May 29-Sunday, May 31. Learn & collab across a variety of approaches, disciplines, and specialties w an engaging lineup of virtual scientific content https://t.co/OkTiL6tiDg

[Douglas K Marks @dougmarksmd]

IO has made IAEs the “GVHD” of solid malignancies. https://t.co/tke3bPBnOY

[Douglas K Marks @dougmarksmd]

To keep on radar — like the term “not negatives” https://t.co/sqsW1vA6zy